Local cortisol activation is involved in EGF-induced immunosuppression

References

• Poumay Y, de Rouvroit CL. HB-EGF, the growth factor that accelerates keratinocyte migration, but slows proliferation. J Invest Dermatol 2012;132:2129–30.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. Journal of immunology 2014;192:859–66.
   PubMed Web of Science ®Google Scholar
• Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008;128:1365–74.
   PubMed Web of Science ®Google Scholar
• Campbell P, Morton PE, Takeichi T, Salam A, Roberts N, Proudfoot LE, Mellerio JE, Aminu K, Wellington C, Patil SN, et al. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol 2014;134:2570–8.
   PubMed Web of Science ®Google Scholar
• Gao HB, Ge RS, Lakshmi V, Marandici A, Hardy MP. Hormonal regulation of oxidative and reductive activities of 11 beta-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 1997;138:156–61.
   PubMed Web of Science ®Google Scholar
• Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC, Stewart PM. Regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J Endocrinol 1998;156:159–68.
   PubMed Web of Science ®Google Scholar
• Terao M, Katayama I. Local cortisol/corticosterone activation in skin physiology and pathology. Journal of dermatological science 2016;84:11–6.
   PubMed Web of Science ®Google Scholar
• Lee B, Vouthounis C, Stojadinovic O, Brem H, Im M, Tomic-Canic M. From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing. Journal of molecular biology 2005;345:1083–97.
   PubMed Web of Science ®Google Scholar
• Terao M, Murota H, Kimura A, Kato A, Ishikawa A, Igawa K, Miyoshi E, Katayama I. 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. PLoS One 2011;6:e25039.
   PubMed Web of Science ®Google Scholar
• Terao M, Itoi S, Murota H, Katayama I. Expression profiles of cortisol-inactivating enzyme, 11beta-hydroxysteroid dehydrogenase-2, in human epidermal tumors and its role in keratinocyte proliferation. Exp Dermatol 2013;22:98–101.
   PubMed Web of Science ®Google Scholar
• Terao M, Itoi S, Matsumura S, Yang L, Murota H, Katayama I. Local Glucocorticoid Activation by 11beta-Hydroxysteroid Dehydrogenase 1 in Keratinocytes: The Role in Hapten-Induced Dermatitis. The American journal of pathology 2016;186:1499–510.
   PubMed Web of Science ®Google Scholar
• Skobowiat C, Sayre RM, Dowdy JC, Slominski AT. Ultraviolet radiation regulates cortisol activity in a waveband-dependent manner in human skin ex vivo. Br J Dermatol 2013;168:595–601.
   PubMed Web of Science ®Google Scholar
• Itoi-Ochi S, Terao M, Murota H, Katayama I. Local corticosterone activation by 11beta-hydroxysteroid dehydrogenase 1 in keratinocytes: the role in narrow-band UVB-induced dermatitis. Dermato-endocrinology 2016;8:e1119958.
   PubMed Web of Science ®Google Scholar
• Tiganescu A, Hupe M, Jiang YJ, Celli A, Uchida Y, Mauro TM, Bikle DD, Elias PM, Holleran WM. UVB induces epidermal 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo. Exp Dermatol 2015;24:370–6.
   PubMed Web of Science ®Google Scholar
• Stoll SW, Rittie L, Johnson JL, Elder JT. Heparin-binding EGF-like growth factor promotes epithelial-mesenchymal transition in human keratinocytes. J Invest Dermatol 2012;132:2148–57.
   PubMed Web of Science ®Google Scholar
• Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab 2008;93:550–6.
   PubMed Web of Science ®Google Scholar
• Takata T, Tarutani M, Zouboulis CC, Sano S. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. Journal of dermatological science 2012;66:165–8.
   PubMed Web of Science ®Google Scholar
• Vukelic S, Stojadinovic O, Pastar I, Rabach M, Krzyzanowska A, Lebrun E, Davis SC, Resnik S, Brem H, Tomic-Canic M. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J Biol Chem 2011;286:10265–75.
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. The oncologist 2016;21:1483–91.
   PubMed Web of Science ®Google Scholar
• Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. International journal of dermatology 2012;51:223–32.
   PubMed Web of Science ®Google Scholar
• Ferrazzi A, Russo I, Pasello G, Alaibac M. Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. Experimental and therapeutic medicine 2016;11:197–200.
   PubMed Web of Science ®Google Scholar
• Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, et al. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 2016;24:301–9.
   PubMed Web of Science ®Google Scholar